Behandling av kronisk myelogen leukemi
dc.contributor.author | Stavem, Per | en |
dc.contributor.author | Hjort, Peter Fredrik | en |
dc.date.accessioned | 2011-04-02T08:47:58Z | nb_NO |
dc.date.accessioned | 2016-02-08T14:18:28Z | |
dc.date.available | 2011-04-02T08:47:58Z | nb_NO |
dc.date.available | 2016-02-08T14:18:28Z | |
dc.date.issued | 1968-12-15 | nb_NO |
dc.identifier.citation | Tidsskrift for den Norske lægeforening 1968, 88 (24):2256-7 | en |
dc.identifier.issn | 0029-2001 | nb_NO |
dc.identifier.uri | http://hdl.handle.net/11250/2377488 | |
dc.language | nor | nb_NO |
dc.language.iso | nob | en |
dc.subject | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Hematologi: 775 | en |
dc.subject.mesh | Busulfan | en |
dc.subject.mesh | Follow-Up Studies | en |
dc.subject.mesh | Humans | en |
dc.subject.mesh | myelogen leukemi | en |
dc.subject.mesh | radioaktivt fosfor | en |
dc.subject.mesh | milten | en |
dc.subject.mesh | myleran | en |
dc.subject.mesh | demecolcin | en |
dc.title | Behandling av kronisk myelogen leukemi | no |
dc.title.alternative | Treatment of chronic myelogenic leukemia | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.source.journal | Tidsskrift for den Norske lægeforening | en |
dc.identifier.pmid | 5250289 | nb_NO |